SynthesisCancer2020
Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
Synthesis in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05541978 (Thrombosis in Newly Diagnosed Multiple Myeloma Patients), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Statin exposure after multiple myeloma diagnosis and risk of all-cause mortality, venous thromboembolism, pathological fractures, and acute kidney injury: a propensity score-matched retrospective cohort study.Annals of medicine and surgery (2012) · 2026Article
- Atrial fibrillation post hematopoietic stem cell transplant: incidence, risk factors, and management challenges.Frontiers in cardiovascular medicine · 2026Review
- Article
- Thromboembolism and bleeding in newly diagnosed multiple myeloma: rates, risk profile, and patterns of thromboprophylaxis.Research and practice in thrombosis and haemostasis · 2025Article
- A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma.Research and practice in thrombosis and haemostasis · 2025Review
- Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.Clinical hematology international · 2025Review
- Supportive care in myeloma-when treating the clone alone is not enough.Hematology. American Society of Hematology. Education Program · 2024Review
- Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines.Annals of hematology · 2024Review
- Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews.Annals of hematology · 2024Review
- Bleeding risk from anticoagulant thromboprophylaxis in patients with multiple myeloma: a MarketScan analysis.Research and practice in thrombosis and haemostasis · 2024Article
- Incidence of thromboembolism and associated factors in multiple myeloma patients treated with immunomodulatory drugs: a retrospective analysis in Belo Horizonte, Brazil.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Risk of thromboembolic events associated with different multiple myeloma regimens in Taiwan: a nested case-control study.Journal of thrombosis and thrombolysis · 2023Article
- Cardiovascular Disease as a Consequence or a Cause of Cancer: Potential Role of Extracellular Vesicles.Biomolecules · 2023Review
- Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.Annals of medicine · 2023Article
- Bleeding risk in patients with multiple myeloma treated for venous thromboembolism: a MarketScan analysis.Research and practice in thrombosis and haemostasis · 2023Article
- Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma.Cancers · 2022Review
- The potential link between Covid-19 and multiple myeloma: A new saga.Immunity, inflammation and disease · 2022Review
- Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from anHaematologica · 2022Article
- How I approach smoldering multiple myeloma.Blood · 2022Review
- Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundThromboprophylaxis is routinely used with lenalidomide-based regimens in multiple myeloma because of a substantial risk of venous thromboembolism (VTE). However, little is known about the incidence of VTE with contemporary lenalidomide-based regimens. The objective of the current study was to estimate the incidence of VTE despite thromboprophylaxis with currently used lenalidomide-based regimens in patients with myeloma.
methodsThe Ovid MEDLINE, Embase, and Cochrane databases were queried from study inception to January 2019 for keywords to cover the following concepts: "lenalidomide," "venous thromboembolism," and "multiple myeloma." Phase 1, 2, and 3 clinical trials evaluating lenalidomide-based regimens with thromboprophylaxis were included. The pooled incidence rate of VTE was estimated using a random-effects model.
resultsThe search generated 1372 citations, with 51 clinical trials and 9069 patients included for analysis. The most common thromboprophylaxis agents were aspirin, low-molecular-weight heparin or warfarin, administered either per risk-stratification or at investigators' discretion. The pooled incidence of VTE in trials of patients who had newly diagnosed and relapsed/refractory myeloma was 6.2% (95% CI, 5.4%-7.1%) over median treatment durations ranging from 2 to 34 cycles, which translated into 1.2 VTE events per 100 patient-cycles (95% CI, 0.9-1.7 VTE events per 100 patient-cycles). Among contemporary regimens, the risk of VTE was low with combined lenalidomide and low-dose dexamethasone (0.2 [95% CI, 0.1-0.6] events/100 patient-cycles) and lenalidomide maintenance (0.0 [95% CI, 0.0-0.7] events per 100 patient-cycles). VTE risk was higher with combined lenalidomide and low-dose dexamethasone plus proteasome inhibitors (1.3 [95% CI, 0.7-2.3] events per 100 patient-cycles).
conclusionsDespite adequate thromboprophylaxis, lenalidomide-based regimens have a substantial risk of VTE in controlled clinical trial settings. Further studies are needed on new thromboprophylaxis strategies with regimens that have a high VTE risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.